ClinicalTrials.gg
Sign In
CompletedNCT03452631Updated Jul 1, 2022

Spontaneous Haematomas of Psoas Occurring in Intensive Care

An observational study in Psoas Hematomas, sponsored by University Hospital, Strasbourg, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by University Hospital, Strasbourg, France · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

Psoas hematomas are a rare and potentially lethal pathology whose incidence in resuscitation is unknown. The pathophysiology of this pathology is not known to date.

02

Conditions studied

  • Psoas Hematomas

Browse trials for

Keywords

  • Psoas hematomas
03

In context

Hematoma

109 studies on the registry are indexed under Hematoma; 19 are open to participants now.

This study's enrollment of 40 is below the median of 113 across 21 observational studies indexed under Hematoma.

Browse Hematoma studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 999 studies on the registry; 358 are open to participants now.

Browse University Hospital, Strasbourg, France studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with psoas hematoma diagnosed during hospitalization

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Major patients
  • Psoas hematoma diagnosed during hospitalization

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
40 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of psoas hematomas

    Time frame: 72 hours after admission to intensive care

07

Study locations

1 site
  • Service de Réanimation médicale
    Strasbourg, 67091, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Dec 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 2, 2018
StartActual
Oct 1, 2017
Primary completionActual
Dec 31, 2017
CompletionActual
Dec 31, 2017
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03452631
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Oct 1, 2017
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017
Last update
Jul 1, 2022

Study contacts

Julie HELMS, MD
study director · University Hospital, Strasbourg, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hematoma →

Other studies from this sponsor

University Hospital, Strasbourg, France →

Start the discussion